同泰大健康主题混合基金共经历4位基金经理的陆续管理，其现任基金经理为马毅和麦健沛，但可惜的 是，至今还没有一位在管理任期内实现正回报。 基金经理变动一览 中国经济网北京2月9日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟 出在哪？》一文。文中称，2021年大量主动权益基金密集成立，但2021年那一批在牛市尾声发车的基金却 并没有集体扬眉吐气。智通财经记者以2021年成立并仍存续的667只主动权益基金为样本统计发现，截至最 新净值，仍有约362只成立以来收益为负，占比超过五成。其中86只基金自成立以来跌幅在30%以上，34只 的回撤更是超过40%。 根据天天基金网最新数据显示，成立于2021年4月8日的同泰大健康主题混合基金A/C，在截至2026年2 月6日的最新累计收益率为-56.45%和-57.28%，累计单位净值仅有0.4355元、0.4272元。 | 同泰大健康主题混合A(011002) | | | | --- | --- | --- | | 单位净值(2026-02-06) | 累计净值 | | | 0.4355 -1.34% | 0.4355 | | | 沂1月: ...

截至发稿，王睿累计任职时间10年286天，现任基金资产总规模57.19亿元，任职期间最佳基金回报 253.09%， 任职期间最差基金回报-32.84%。 朱慧灵累计任职时间311天，现任基金资产总规模2.42亿元，任职期间最佳基金回报5.19%， 任职期间 最差基金回报5.1%。 从基金十大重仓股角度 数据显示，中信保诚基金旗下1只基金重仓舒泰神。中信保诚至瑞混合A（003432）四季度增持6万股， 持有股数35.5万股，占基金净值比例为4%，位居第六大重仓股。根据测算，今日浮盈赚取约55.03万 元。连续3天上涨期间浮盈赚取90.17万元。 中信保诚至瑞混合A（003432）成立日期2016年10月21日，最新规模1.34亿。今年以来收益0.45%，同 类排名7442/8873；近一年收益5.69%，同类排名7141/8123；成立以来收益70.61%。 中信保诚至瑞混合A（003432）基金经理为王睿、朱慧灵。 2月6日，舒泰神涨5.65%，截至发稿，报29.00元/股，成交4.37亿元，换手率3.45%，总市值138.55亿 元。舒泰神股价已经连续3天上涨，区间累计涨幅10.2%。 资料显示，舒泰神(北 ...

每经AI快讯，2月6日，创新药概念盘中震荡反弹， 广生堂涨超10%，诺诚健华、舒泰神、科伦药业、 三生国健、美迪西、诺思兰德冲高。 （文章来源：每日经济新闻） ...

2月5日早盘，创新药概念股拉升，广生堂涨超13%，方盛制药、舒泰神、通化东宝、翰宇药业、盘龙药 业等涨幅居前。 ...

Group 1 - The core index of the biotechnology sector, the Biotechnology Index (970038), closed at 2197.03 points, reflecting a 0.91% increase with a trading volume of 21.69 billion and a turnover rate of 2.07% [1] - Among the constituent stocks of the Biotechnology Index, 40 stocks experienced an increase, with Shutai Shen leading the gain at 4.14%, while 10 stocks saw a decline, with Deep Technology leading the drop at 5.09% [1] Group 2 - In terms of capital flow, the Biotechnology Index's constituent stocks experienced a net outflow of 352 million from major funds, while retail funds saw a net outflow of 11.73 million [2] - Conversely, there was a net inflow of 364 million from speculative funds into the Biotechnology Index [2]

Market Overview - The chemical pharmaceutical sector increased by 0.76% on February 4, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Gainers in Chemical Pharmaceutical Sector - Guangshantang (300436) closed at 116.01, up 7.50% with a trading volume of 144,300 shares and a transaction value of 16.55 billion [1] - Xinlitai (002294) closed at 48.15, up 4.27% with a trading volume of 118,000 shares and a transaction value of 564 million [1] - Zehao Pharmaceutical (688266) closed at 90.30, up 4.19% with a trading volume of 31,500 shares and a transaction value of 280 million [1] - Other notable gainers include Puluo Pharmaceutical (000739) and Shutaishen (300204), with increases of 4.17% and 4.14% respectively [1] Top Losers in Chemical Pharmaceutical Sector - Xinnoway (300765) closed at 35.80, down 3.79% with a trading volume of 126,300 shares [2] - Tonghua Jinma (000766) closed at 23.57, down 3.72% with a trading volume of 352,100 shares and a transaction value of 814 million [2] - Changshan Pharmaceutical (300255) closed at 48.63, down 3.09% with a trading volume of 246,200 shares and a transaction value of 1.186 billion [2] Capital Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 39.83 million from institutional investors, while retail investors experienced a net outflow of 190 million [2][3] - Notable net inflows from institutional investors include ST Renfu (600079) with 123 million and Guangshantang (300436) with 110 million [3] - Retail investors showed significant outflows from ST Renfu (600079) and Guangshantang (300436), with outflows of 71.99 million and 86.96 million respectively [3]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovative development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63%, with a total market value of 4.285 billion [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion [2] - Shutaishen rose by 3.94%, with a total market value of 1.3 billion [2] - Beilu Pharmaceutical increased by 3.49%, with a total market value of 584.3 million [2] - Tigermed rose by 3.37%, with a total market value of 56.3 billion [2]

Group 1 - The innovative drug sector experienced a significant upward trend on February 4, with notable gains in several companies [2] - HaiTe Bio saw an increase of over 8%, while GuangShengTang rose by more than 6% [2] - Other companies such as KangChen Pharmaceutical, ShuTaiShen, XinLiTai, BeiLu Pharmaceutical, and Tigermed also showed positive movement in their stock prices [2]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovation and development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63% with a total market value of 42.85 billion and a year-to-date increase of 18.07% [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion and a year-to-date increase of 29.53% [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion and a year-to-date increase of 4.53% [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion and a year-to-date decrease of 2.89% [2] - Shutaishen and Beilu Pharmaceutical both saw increases of over 3%, with market values of 13 billion and 5.843 billion respectively [2]

1月30日，舒泰神涨0.63%，成交额3.95亿元。两融数据显示，当日舒泰神获融资买入额2081.25万元， 融资偿还1760.02万元，融资净买入321.23万元。截至1月30日，舒泰神融资融券余额合计1.33亿元。 融资方面，舒泰神当日融资买入2081.25万元。当前融资余额1.33亿元，占流通市值的1.08%。 融券方面，舒泰神1月30日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 截至9月30日，舒泰神股东户数4.65万，较上期增加46.97%；人均流通股9745股，较上期减少31.98%。 2025年1月-9月，舒泰神实现营业收入1.81亿元，同比减少30.82%；归母净利润-3068.95万元 ...